Disease Overview：Pulmonary Alveolar Microlithiasis（PAM）
Pulmonary alveolar microlithiasis (PAM) is a rare, chronic, progressive interstitial lung disease characterized by the intra-alveolar accumulation of calcium phosphate microliths. It results from mutations in the SLC34A2 gene, leading to dysfunctional type II alveolar epithelial cell transport of inorganic phosphate and subsequent mineral deposition. Symptoms—often insidious—include dry cough, dyspnea on exertion, and recurrent respiratory infections; many patients remain asymptomatic for years despite extensive radiographic abnormalities, notably bilateral “sandstorm” or “ground-glass” opacities on high-resolution CT. Diagnosis relies on imaging findings combined with bronchoalveolar lavage showing calcified microliths or histopathological confirmation. No disease-modifying pharmacotherapy exists; management focuses on supportive care, oxygen supplementation, and monitoring for complications such as pulmonary hypertension or respiratory failure. Lung transplantation remains the only definitive intervention for end-stage disease.
China offers distinct advantages for PAM evaluation and management. Leading respiratory centers—such as Peking Union Medical College Hospital and Shanghai Pulmonary Hospital—house multidisciplinary teams with deep expertise in rare interstitial lung diseases and access to advanced diagnostic tools including ultra-high-resolution CT, quantitative lung densitometry, and genetic sequencing. Several documented cases demonstrate successful long-term stabilization through tailored surveillance protocols and timely transplant referral pathways. Treatment costs—including comprehensive diagnostics, specialist consultations, and potential transplant evaluation—are typically 40–60% lower than in Western Europe or the U.S., without compromising clinical rigor or regulatory compliance. As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying hospital credentials, coordinating appointments with pulmonologists and transplant surgeons, providing itemized, transparent pricing in advance, and offering end-to-end support—from visa assistance and accommodation to post-consultation follow-up coordination.
Pulmonary Alveolar Microlithiasis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Pulmonary Alveolar Microlithiasis (PAM)
Non-Surgical / Conservative Management
*No disease-modifying therapy exists; treatment focuses on symptom control, monitoring, and complication prevention.*
- •Bronchodilators (e.g., salbutamol inhaler): For reversible airflow limitation (FEV₁/FVC < 0.7 + bronchodilator response ≥12%): ¥80–¥120/month ($11–$17)
- •Low-dose inhaled corticosteroids (e.g., budesonide 200 μg BID): Only if coexisting eosinophilic bronchitis or asthma phenotype confirmed by sputum eosinophils >3%: ¥150–¥220/month ($21–$31)
- •Oxygen therapy (home concentrator, ≥2 L/min): Required for resting SpO₂ ≤92% or exercise desaturation (6MWT SpO₂ <88%): Device rental ¥400/month ($56); nasal cannula + tubing ¥60 ($8)
- •Annual monitoring: High-resolution CT (HRCT) chest + PFTs (spirometry, DLCO, lung volumes): ¥1,200–¥1,600 ($168–$224)
- •Lab fees: Serum calcium, phosphate, PTH, KL-6 (biomarker of alveolar injury): ¥380 ($53)
Surgical / Procedural Options
*Only considered for end-stage respiratory failure unresponsive to conservative care.*
- •Eligibility: FVC <50% predicted, DLCO <30% predicted, progressive hypoxemia (PaO₂ ≤55 mmHg on room air), no contraindications to major surgery (e.g., severe cardiac comorbidity).
- •Lung transplantation (bilateral sequential):
- First-year immunosuppression (tacrolimus, mycophenolate, prednisone): ¥45,000 (
$6,300)Special / Complex Condition Management
- •
Quick Selection Guide
- •
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Pulmonary Alveolar Microlithiasis Medical Vacation Packages
Curated transparent all-inclusive packages combining Pulmonary Alveolar Microlithiasis treatment with China top medical destinations:
